These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 9933661)

  • 1. Comparison of iodine-123 epidepride and iodine-123 IBZM for dopamine D2 receptor imaging in clinically non-functioning pituitary macroadenomas and macroprolactinomas.
    de Herder WW; Reijs AE; de Swart J; Kaandorp Y; Lamberts SW; Krenning EP; Kwekkeboom DJ
    Eur J Nucl Med; 1999 Jan; 26(1):46-50. PubMed ID: 9933661
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vivo imaging of pituitary tumours using a radiolabelled dopamine D2 receptor radioligand.
    de Herder WW; Reijs AE; Kwekkeboom DJ; Hofland LJ; Nobels FR; Oei HY; Krenning EP; Lamberts SW
    Clin Endocrinol (Oxf); 1996 Dec; 45(6):755-67. PubMed ID: 9039343
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dopamine D2 receptor imaging in pituitary adenomas using iodine-123-epidepride and SPECT.
    Pirker W; Riedl M; Luger A; Czech T; Rössler K; Asenbaum S; Angelberger P; Kornhuber J; Deecke L; Podreka I; Brücke T
    J Nucl Med; 1996 Dec; 37(12):1931-7. PubMed ID: 8970508
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of iodine-123-epidepride and iodine-123-IBZM for dopamine D2 receptor imaging.
    Leslie WD; Abrams DN; Greenberg CR; Hobson D
    J Nucl Med; 1996 Oct; 37(10):1589-91. PubMed ID: 8862288
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnostic imaging of dopamine receptors in pituitary adenomas.
    de Herder WW; Reijs AEM; Feelders RA; van Aken MO; Krenning EP; van der Lely AJ; Kwekkeboom DJ
    Eur J Endocrinol; 2007 Apr; 156 Suppl 1():S53-S56. PubMed ID: 17413189
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlation of scintigraphic results using 123I-methoxybenzamide with hormone levels and tumor size response to quinagolide in patients with pituitary adenomas.
    Ferone D; Lastoria S; Colao A; Varrella P; Cerbone G; Acampa W; Merola B; Salvatore M; Lombardi G
    J Clin Endocrinol Metab; 1998 Jan; 83(1):248-52. PubMed ID: 9435450
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hormone levels and tumour size response to quinagolide and cabergoline in patients with prolactin-secreting and clinically non-functioning pituitary adenomas: predictive value of pituitary scintigraphy with 123I-methoxybenzamide.
    Colao A; Ferone D; Lastoria S; Cerbone G; Di Sarno A; Di Somma C; Lucci R; Lombardi G
    Clin Endocrinol (Oxf); 2000 Apr; 52(4):437-45. PubMed ID: 10762286
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dopamine agonist therapy of clinically non-functioning pituitary macroadenomas. Is there a role for 123I-epidepride dopamine D2 receptor imaging?
    de Herder WW; Reijs AE; Feelders RA; van Aken MO; Krenning EP; Tanghe HL; van der Lely AJ; Kwekkeboom DJ
    Eur J Endocrinol; 2006 Nov; 155(5):717-23. PubMed ID: 17062888
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Iodine-123-IBZM-SPECT: studies in 15 patients with pituitary tumors.
    Pirker W; Brücke T; Riedl M; Clodi M; Luger A; Asenbaum S; Podreka I; Deecke L
    J Neural Transm Gen Sect; 1994; 97(3):235-44. PubMed ID: 7873131
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolism of [123I]epidepride may affect brain dopamine D2 receptor imaging with single-photon emission tomography.
    Bergström KA; Yu M; Kuikka JT; Akerman KK; Hiltunen J; Lehtonen J; Halldin C; Tiihonen J
    Eur J Nucl Med; 2000 Feb; 27(2):206-8. PubMed ID: 10755727
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Absolute quantitation of iodine-123 epidepride kinetics using single-photon emission tomography: comparison with carbon-11 epidepride and positron emission tomography.
    Almeida P; Ribeiro MJ; Bottlaender M; Loc'h C; Langer O; Strul D; Hugonnard P; Grangeat P; Mazière B; Bendriem B
    Eur J Nucl Med; 1999 Dec; 26(12):1580-8. PubMed ID: 10638410
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Single photon emission tomography (SPET) imaging of dopamine D2 receptors in the course of dopamine replacement therapy in patients with nocturnal myoclonus syndrome (NMS).
    Staedt J; Stoppe G; Kögler A; Riemann H; Hajak G; Munz DL; Emrich D; Rüther E
    J Neural Transm Gen Sect; 1995; 99(1-3):187-93. PubMed ID: 8579804
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Dopamine (D2) receptor SPECT with 123I-iodobenzamide (IBZM) in diagnosis of Parkinson syndrome].
    Reiche W; Grundmann M; Huber G
    Radiologe; 1995 Nov; 35(11):838-43. PubMed ID: 8657887
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vivo visualization of pituitary dopaminergic receptors by iodine-123 methoxybenzamide (IBZM) correlates with sensitivity to dopamine agonists in two patients with macroprolactinomas.
    Scillitani A; Dicembrino F; Di Fazio P; Vettori PP; D'Angelo V; Scarabino T; Liuzzi A
    J Clin Endocrinol Metab; 1995 Aug; 80(8):2523-5. PubMed ID: 7629253
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The discovery of epidepride and its analogs as high-affinity radioligands for imaging extrastriatal dopamine D(2) receptors in human brain.
    de Paulis T
    Curr Pharm Des; 2003; 9(8):673-96. PubMed ID: 12570798
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of [123I]IBZM pinhole SPECT for the detection of striatal dopamine D2 receptor availability in rats.
    Scherfler C; Scholz SW; Donnemiller E; Decristoforo C; Oberladstätter M; Stefanova N; Diederen E; Virgolini I; Poewe W; Wenning GK
    Neuroimage; 2005 Feb; 24(3):822-31. PubMed ID: 15652317
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of endogenous dopamine release by methylphenidate challenge using iodine-123 iodobenzamide single-photon emission tomography.
    Booij J; Korn P; Linszen DH; van Royen EA
    Eur J Nucl Med; 1997 Jun; 24(6):674-7. PubMed ID: 9169577
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Iodine-123-epidepride-SPECT: studies in Parkinson's disease, multiple system atrophy and Huntington's disease.
    Pirker W; Asenbaum S; Wenger S; Kornhuber J; Angelberger P; Deecke L; Podreka I; Brücke T
    J Nucl Med; 1997 Nov; 38(11):1711-7. PubMed ID: 9374338
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vivo measurement of haloperidol affinity to dopamine D2/D3 receptors by [123I]IBZM and single photon emission computed tomography.
    Videbaek C; Toska K; Friberg L; Holm S; Angelo HR; Knudsen GM
    J Cereb Blood Flow Metab; 2001 Jan; 21(1):92-7. PubMed ID: 11149673
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Imaging of dopamine D2 and somatostatin receptors in vivo using single-photon emission tomography in a patient with a TSH/PRL-producing pituitary macroadenoma.
    Verhoeff NP; Bemelman FJ; Wiersinga WM; van Royen EA
    Eur J Nucl Med; 1993 Jun; 20(6):555-61. PubMed ID: 8339737
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.